Introduction
Erectile dysfunction (ED) is the persistent inability to achieve and/or maintain an erection sucient for satisfactory sexual intercourse, 1 and is a common result of spinal cord injury (SCI). 2 Although many patients with SCI retain some re¯exogenic or psychogenic erectile function, these erections are frequently unsuitable for satisfactory sexual activity. 2 Treatment for ED includes injections of vasoactive substances, vacuum constrictive devices, and penile prosthesis implants. 3 ± 7 However, these methods are cumbersome, resulting in a high rate of drop-out. 1 
VIAGRA
1 (sildena®l citrate) is an oral agent for the treatment of ED. Sildena®l has proven both eective and well tolerated in patients with ED of broad-spectrum etiology 8 ± 10 and in patients with SCI. 11 ± 13 Sildena®l selectively inhibits the enzyme phosphodiesterase (PDE) type 5, the enzyme responsible for breakdown of cyclic guanosine monophosphate (cGMP) in the corpus cavernosum. 14, 15 Sildena®l enhances the relaxant eect of nitric oxide, 15, 16 which results in activation of guanylate cyclase, thereby elevating the levels of cGMP. The increased levels of cGMP lead to smooth muscle relaxation, resulting in an erection.
The National Institutes of Health (NIH) Consensus Development Panel on Impotence 1 has recommended that studies be conducted to determine the social and psychological eects of ED on patients and partners. The withdrawal of men from their intimate relationships because of fears of inadequate sexual performance or rejection may have a negative eect on overall health. 1 The evaluation and treatment of ED should be dictated by patient motivation, expectations, and physical and mental health. 17 Not only will the treatment of ED improve the male's intimate relation-ships but will also improve that of the partner, who may also experience increased anxiety 1 and a poorer quality of life (QoL). 18 In general, average QoL scores are signi®cantly lower in patients with SCI than in the nondisabled population. 19, 20 Patients with SCI have a greater propensity for a poorer QoL than patients without SCI, not only because the injury results in physical limitations, but also because of psychosocial problems, such as barriers to social relationships and the fact that persons tend to reject close and intimate relationships with disabled people. 21 Therefore, SCI may have a profound eect on the patient's sexuality, 22 resulting in a signi®cant decrease in satisfaction with sexual life, an important predicator of satisfaction with life as a whole. 23 Presumably, a lower QoL, primarily from the anxiety and depression that patients with SCI suer, is exacerbated by the sense of depression and poor selfimage associated with ED. 1, 19, 24 The trauma of the injury may also place a great strain on the sexuality of the partner in an existing relationship 25 and increase the anxiety levels of the patient with SCI. Approximately half of preinjury partners and a quarter of postinjury partners reported decreased sexual interest due to the injury. 26 The interrelated nature of ED, SCI, and QoL warrants the inclusion in clinical trials of an assessment of QoL. This can properly address the ecacy of any therapy on overall sexual functioning and its physical, psychological, and social impact. The importance of QoL in assessing treatment in patients with SCI is underscored by the belief that levels of social and psychological functioning are more important predictors of life satisfaction than the seriousness of the injury in patients with SCI. 27 
Objectives
The ecacy of oral sildena®l to improve erections has been demonstrated in men with ED attributable to SCI; 12, 13 however, any improvement in QoL resulting from improvements in sexual functioning have not yet been examined in men receiving sildena®l for the treatment of ED attributable to SCI. The ecacy of sildena®l has been assessed in the men with ED and SCI used in this investigation. 11 The evaluation of the eect of sildena®l treatment on condition-speci®c and general QoL parameters in men with ED caused by SCI is reported.
Methods

Study population
Quality of life (QoL) was evaluated in a randomized, double-blind, placebo-controlled, two-way crossover, exible-dose study of 178 men with ED caused by SCI (151 men had residual psychogenic or re¯exogenic erectile function and 27 men had no residual erectile function) at 19 centers in Europe and Australia. All participants conformed to speci®c inclusion and exclusion criteria. Main inclusion criteria were as follows: men at least 18 years of age, a traumatic SCI at least 6 months before screening, a clinical diagnosis of ED solely attributable to injury of the spinal cord, cessation of other therapies for ED, and involvement in a stable relationship with a female partner for at least the past 6 months. The main exclusion criteria were the following: laboratory abnormalities; genital anatomical deformities; primary sexual disorder other than ED; major psychiatric or psychological disorder, including major depression; diabetes mellitus; history of stroke or myocardial infarction within the last 6 months; any signi®cant cardiovascular disease within the last 6 months; regular nitrate therapy; active peptic ulcers; history of retinitis pigmentosa, bleeding disorders, or renal or hepatic abnormalities; and evidence of other medical conditions impairing ability to complete the study. These men were the same participants used to assess the ecacy of sildena®l in patients with SCI.
11
Patients attended the clinic on ®ve occasions: at screening, at the start and end of the ®rst double-blind treatment period, and at the start and end of the second double-blind treatment period. Laboratory safety tests were performed at screening and at the end of each treatment period.
Dosing
Following a 4-week run-in period, each patient underwent two 6-week crossover periods with a 2-week washout period between the crossover periods. The run-in period could be reduced to 2 weeks if patients had not taken any other treatment for their ED during the 2 weeks before screening. Patients were randomized to receive either 6 weeks of¯exible-dose sildena®l treatment followed by 6 weeks of matching placebo or 6 weeks of placebo followed by 6 weeks of exible-dose sildena®l treatment.
Patients were instructed to take 50 mg of sildena®l or matching placebo approximately 1 h before sexual activity but not more than once daily. Depending on ecacy and tolerability, the dose was increased to a maximum of 100 mg or adjusted downward to 25 mg over the 6-week treatment period. Patients were asked to complete an event log about sexual intercourse each time they took a dose of drug or engaged in sexual activity and what dosage was taken. Patients were discontinued from the study if a dose caused unacceptable adverse events.
Clinical assessments
The ecacy of sildena®l treatment on the improvement on erections was evaluated using a global ecacy question (`Did treatment improve your erections?'). The validated 15-item International Index of Erectile Function (IIEF) is a reliable, self-administered questionnaire with the sensitivity and speci®city for detecting treatment-related changes in patients with ED in research or clinical settings. 28 The 15 questions of the IIEF can be divided into ®ve domains that address erectile function, orgasmic function, sexual desire, intercourse satisfaction, and overall satisfaction with sexual life. Patients completed the IIEF at baseline and at the end of treatment for each treatment period.
Responses to questions 13 and 14 of the IIEF, which comprise the overall satisfaction with sexual life domain of the IIEF, speci®cally address QoL issues related to sexual dysfunction. Question 13 asks,`How satis®ed have you been with your overall sex life? and question 14 asks,`How satis®ed have you been with your sexual relationship with your partner?' These questions are scored on a scale of 1 (`very dissatis®ed') to 5 (`very satis®ed'). Responses to other IIEF questions were previously published.
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Quality of life was also assessed using one instrument speci®cally designed to assess the impact of erectile problems on QoL and four broad-based, psychometric QoL instruments that are commonly used for comparisons involving generic health concepts at baseline and at the end of each 6-week treatment period ( Table 1 ). The speci®c impact of erectile problems on QoL was assessed using the 5-item Impact of Erectile Problems questionnaire. 29 The ®ve questions ask about concerns associated with erection problems (feelings of frustration, discouragement, despair, worry, and being weighed down by erectile problems). Each question is scored on a scale of 1 (`all of the time') to 6 (`none of the time').
The general QoL instruments, which address more global concepts of life satisfaction (see Table 1 for scoring scales and types of questions), included the 12-item Medical Outcomes Survey Short Form (MOS SF-12), 30 adapted from the 36-item MOS SF-36 survey, 31 and the 14-item Psychological General Well-Being (PGWB) Index, adapted from the 22-item PGWB Index. 32 The MOS SF-12 is a brief measure of overall functional health (mental and physical) status, 33 and the PGWB Index is a measure of psychological well-being. 32 Questions 3 and 4 from the SF-12 questionnaire were not applicable to patients with SCI and therefore not completed. Individual scores for survey questions in these two instruments were summed by physical and mental health components for the MOS SF-12 survey and by anxiety, positive well-being, self-control, and 
Statistical analysis
Patients with residual (psychogenic and/or re¯exogenic) erectile function and patients with no residual erectile function at baseline were included in all analyses, unless noted dierently. Responses to IIEF questions, the partner questionnaire, and QoL data were analyzed using analysis of covariance (ANCOVA) and included terms for treatment eect, center eect, baseline eect, treatment-by-baseline interaction, and treatment-bycenter interaction. Age, duration of ED, smoking status, period, sequence (carryover), and residual erectile function status were used as covariate terms. Results using ANCOVA for these data have been successfully submitted in regulatory ®lings for sildena®l. Ecacy and QoL comparisons were made between sildena®l (all doses) and placebo. All tests were twotailed and evaluated at the 5% level for signi®cance of treatment eect (that is, sildena®l versus placebo).
Safety analysis
Adverse events that occurred during treatment or within 7 days of the end of treatment were recorded and are as previously reported. 11 The level of discontinuation during sildena®l treatment (3.4%) was similar to that during placebo treatment (2.3%).
Results
The demographics of the 178 patients randomized to treatment in the two sequence groups were nearly identical and are shown in Table 2 . The mean age of patients with SCI in both sequence groups was 38 years (range 19 ± 63 years) with 11 years mean duration of SCI since its diagnosis for both sequence groups. Approximately 85% of the patients reported residual erectile function at baseline; 15% reported no residual erectile function at baseline. Patients in both sequence groups also showed a similar tendency in dosage of sildena®l and placebo taken (Table 3 ). There was a trend toward taking the higher doses of placebo (ranging from 4% at 25 mg to 81% at 100 mg) than of sildena®l (5% at 25 mg to 59% at 100 mg).
Because sexual function aects QoL, it was necessary to assess that oral sildena®l improved sexual function in the patients with SCI in this study. Published results on the same study population found a signi®cantly improved ability to have intercourse for patients with SCI who received sildena®l (80%) compared with those who received placebo (10%), a signi®cant preference for sildena®l treatment over placebo by 95% of the patients, and statistically signi®cant improvements in the ability to obtain and maintain erections with sildena®l treatment versus placebo (P50.0001).
11 Patients (64%) with no residual erectile function also stated a preference for sildena®l versus placebo.
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Queries from the IIEF relating treatment to overall satisfaction with sex life (Q13) and sexual relationship with partner (Q14) resulted in signi®cant improvements with sildena®l treatment compared with placebo (P50.0001) (Figure 1 ). The mean score for Q13 of the IIEF increased by 49% over baseline for patients receiving sildena®l, which was signi®cantly greater Figure 2 ). Statistically signi®cant (P50.05) improvements in favor of sildena®l at the end of treatment were seen in four out of the 10 general mental, physical, and psychosocial parameters. These improvements are shown in Table 4 and were the PGWB Index parameters of`anxiety',`depression', and`well-being' and the MOS SF-12 mental health component summary score. At the end of treatment, the mean score for PGWB`depression' decreased with placebo (Figure 3 ). Although the dierence is statistically signi®cant, it may not be clinically signi®cant. The mean scores for the other three parameters improved by 3.6% to 8% from baseline for patients receiving sildena®l versus 1.2% to 4.7% for patients receiving placebo (P50.05 for treatment eect for all comparisons) (Figure 3 ). There were no signi®cant dierences in end-oftreatment scores between patients receiving sildena®l and patients receiving placebo for the PGWB Index measure of self-control, the MOS Family Survey, health compared with 1 year ago, or the MOS SF-12 physical summary score.
Discussion
Seventy-eight per cent of SCI lesions are in persons 40 years of age or younger. 35 Although SCI profoundly aects the patient's sexuality 22 at any age, some older men with SCI may be willing to accept ED more than younger patients with SCI. 36 An increasingly younger patient population with SCI and greatly improved survival rates in patients with SCI have shifted the treatment emphasis toward enhancing the quality of life.
2 Because sexuality is an important factor in QoL 23 and ED is a common consequence of SCI, assessing QoL in patients with SCI is an important part of treatment as well as a way of assessing the overall ecacy of therapeutic interventions for ED. A previous report indicated an improvement in QoL with a vacuum erection device but a loss of erection during sexual activity, resulting in 67% discontinuation of treatment in the sample population. 36 Penile prostheses and prostaglandin E 1 treatment improved the QoL of patients with SCI as well; however, for patients with SCI and ED, complications resulted from penile implants and prostaglandin E 1 treatment, 6, 36, 37 underscoring the importance of an eective and noninvasive treatment for ED.
To determine if sildena®l was eective in improving QoL in patients with SCI and ED, the eects of sildena®l on ED in patients with SCI for improvement of sexual function were examined, and those results have been published. 11 Almost all patients with SCI who reported signi®cant improvement in the ability to have intercourse with sildena®l treatment would continue sildena®l treatment if it were available. Improvement in the ability to have intercourse was re¯ected in the responses to IIEF questions concerning frequency of penetration and frequency of maintained erections. These results are similar to those reported for nondisabled men with ED. 8 Oral sildena®l has previously been found to be eective in improving sexual function in men with SCI. 12, 13 Because sexual dysfunction, SCI and QoL are interrelated and treatment with oral sildena®l has been found to be eective in improving sexual function, it was expected that sildena®l would improve QoL in patients with SCI and ED. All parameters speci®cally relating QoL and ED showed signi®cant improvements in the mean scores. Patients with SCI reported increased satisfaction with their sex life (Q13 of the IIEF) and their sexual relationship (Q14 of the IIEF). Patients also were less concerned about their erectile problems (for example, less worry, frustration, despair) than patients receiving placebo. A previous study found that patients with SCI taking sildena®l did report an improvement in satisfaction with their sex life, but this study was limited by the small number of patients (12) , limited number of QoL assessments, and inclusion only of men with SCI with re¯exogenic erections. 13 The lack of improvement in mean scores in response to the general satisfaction with relationship question (MOS Q7) in this study may be due to the criteria for patients in this study, which included patients with SCI who were in a stable relationship and had a traumatic SCI 6 months before screening. A sexual relationship for patients with SCI is unlikely to be spontaneous: patients and their partners are more likely to have discussed sex in advance, allowing for patients with SCI to have overcome or learned to deal with their ED. Patients with SCI in postinjury marriages were signi®cantly more satis®ed than patients with SCI in preinjury marriages with their living arrangements and sex lives (P50.001), as well as their social lives, general health (P50.01), emotional adjustment, and sense of control over their lives . 38 Litwin and colleagues 39 showed that there was no signi®cant correlation between sexual bother (level of interference or annoyance by ED) and marital interaction in men with ED, and sexual bother did not correlate with any of the general QoL domains.
Other QoL instruments used in this study did not speci®cally relate sexual function with QoL, yet there were statistically signi®cant improvements following treatment with sildena®l in four of the QoL parameters. There were statistically signi®cant (P50.05) improvements in the MOS SF-12 mental health component (psychological distress and wellbeing) score and the PGWB positive well-being, depression, and anxiety indices. An improvement in mental health and positive well-being is likely due to an improved sex life, improved sexual relationship with partner, and reduced concerns about erectile problems and inadequate sexual performance. A high association between overall well-being and emotional problems and sexual dysfunction was recently reported. 40 It is important to note that there were signi®cant improvements in mean scores of anxiety and depression with sildena®l treatment. Both anxiety and depression are primary psychological consequences of SCI. 24 Anxiety and depression signi®cantly improved with sildena®l, suggesting that decreased sexual functioning does diminish QoL in patients with SCI, despite other reports. A signi®cant improvement in anxiety was not seen in patients with residual erectile function. This suggests that improvement in erectile function reduced anxiety most in patients with no residual erectile function at baseline. There was a decline in the depression index with placebo treatment, indicating an increased level of depression at the end of the treatment compared to baseline. It is possible that the expectation of success led to discouragement and a decline in the placebo-treated patients. Patients were excluded from this study if they had depression, and this sample population is not representative of the total SCI male population. The exclusion of patients with depression will give higher overall baseline values than would normally be seen in a group of men without such an exclusion criterion.
A shortcoming of this study may be that results were based on only 6 weeks of treatment with sildena®l, and it is possible that with a larger sample size and a longer duration of sildena®l treatment, signi®cant changes in other QoL parameters would be seen. Studies measuring eectiveness of other ED therapies on QoL in nondisabled men did not show signi®cant improvements until 6 months after baseline. 18, 41 Not all QoL parameters measured in this study showed statistically signi®cant improvements because an improvement in erectile function is unlikely to improve perceived general health, physical function, emotional stability, and general communication and satisfaction with partner. This may be explained by the relatively high baseline scores, due to the strict inclusion criteria, allowing little room for improvement. Patients with SCI in a relationship are more likely to have adapted other means of sexual grati®cation, especially among younger couples. 26 The same study reported that many relationships were satisfactory in which one person has an SCI, even in the absence of sexual activity. 26 Although patients with SCI may be able to cope with their lack of sexual performance by either avoidance (38% of male patients with SCI never try sexual intercourse after their injury 42 ) or other means, this does not suggest that men with ED attributable to SCI cannot improve their QoL and their sexual functioning through treatment with sildena®l.
This report ®nds that the QoL of men with ED attributable to SCI is signi®cantly improved with oral sildena®l treatment. QoL parameters directly related to sexual function showed the greatest improvement. Some general QoL parameters also showed signi®cant improvements and are the parameters most likely aected by a patient with SCI and ED. Other QoL parameters were perhaps not sensitive enough to detect important changes in patients with SCI with ED. These results demonstrate the importance of using condition-speci®c parameters to address the interrelatedness of QoL, SCI, and ED.
Conclusions
Treatment with sildena®l can signi®cantly improve erectile function in men with SCI, including men with no residual erectile function. 11 Overall, the conditionspeci®c QoL measures related to sexual function showed signi®cant improvements after treatment with sildena®l and correlated well with the ecacy in men with ED attributable to SCI. The most dramatic improvement in QoL was seen in the overall satisfaction with sexual life domain of the IIEF, followed by being less bothered by the`impact of erectile problems' and improvements in`mental health' and`depression'. No signi®cant improvements were seen in perceived general health, physical function, emotional stability, and general communication and satisfaction with partner.
